Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
Identifieur interne : 001985 ( Ncbi/Merge ); précédent : 001984; suivant : 001986Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
Auteurs : Joshua M. Dinapoli [États-Unis] ; Alexander Kotelkin ; Lijuan Yang ; Subbiah Elankumaran ; Brian R. Murphy ; Siba K. Samal ; Peter L. Collins ; Alexander BukreyevSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2007.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Animaux, Cytométrie en flux, Immunisation (), Maladies transmissibles émergentes (), Maladies transmissibles émergentes (immunologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vecteurs génétiques (immunologie), Virus de la maladie de Newcastle (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux.
- immunologie : Maladies transmissibles émergentes, Vaccins antiviraux, Vecteurs génétiques, Virus de la maladie de Newcastle, Virus du SRAS.
- Administration par voie nasale, Animaux, Cytométrie en flux, Immunisation, Maladies transmissibles émergentes.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Chlorocebus aethiops, Communicable Diseases, Emerging (immunology), Communicable Diseases, Emerging (prevention & control), Flow Cytometry, Genetic Vectors (immunology), Immunization (methods), Newcastle disease virus (immunology), SARS Virus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- immunology : Communicable Diseases, Emerging, Genetic Vectors, Newcastle disease virus, SARS Virus, Viral Vaccines.
- methods : Immunization.
- prevention & control : Communicable Diseases, Emerging.
- Administration, Intranasal, Animals, Chlorocebus aethiops, Flow Cytometry.
Abstract
The international outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in 2002-2003 highlighted the need to develop pretested human vaccine vectors that can be used in a rapid response against newly emerging pathogens. We evaluated Newcastle disease virus (NDV), an avian paramyxovirus that is highly attenuated in primates, as a topical respiratory vaccine vector with SARS-CoV as a test pathogen. Complete recombinant NDV was engineered to express the SARS-CoV spike S glycoprotein, the viral neutralization and major protective antigen, from an added transcriptional unit. African green monkeys immunized through the respiratory tract with two doses of the vaccine developed a titer of SARS-CoV-neutralizing antibodies comparable with the robust secondary response observed in animals that have been immunized with a different experimental SARS-CoV vaccine and challenged with SARS-CoV. When animals immunized with NDV expressing S were challenged with a high dose of SARS-CoV, direct viral assay of lung tissues taken by necropsy at the peak of viral replication demonstrated a 236- or 1,102-fold (depending on the NDV vector construct) mean reduction in pulmonary SARS-CoV titer compared with control animals. NDV has the potential for further development as a pretested, highly attenuated, intranasal vector to be available for expedited vaccine development for humans, who generally lack preexisting immunity against NDV.
DOI: 10.1073/pnas.0703584104
PubMed: 17535926
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001D96
- to stream PubMed, to step Curation: 001D96
- to stream PubMed, to step Checkpoint: 001D53
Links to Exploration step
pubmed:17535926Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.</title><author><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kotelkin, Alexander" sort="Kotelkin, Alexander" uniqKey="Kotelkin A" first="Alexander" last="Kotelkin">Alexander Kotelkin</name></author><author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></author><author><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17535926</idno><idno type="pmid">17535926</idno><idno type="doi">10.1073/pnas.0703584104</idno><idno type="wicri:Area/PubMed/Corpus">001D96</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D96</idno><idno type="wicri:Area/PubMed/Curation">001D96</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D96</idno><idno type="wicri:Area/PubMed/Checkpoint">001D53</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D53</idno><idno type="wicri:Area/Ncbi/Merge">001985</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.</title><author><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kotelkin, Alexander" sort="Kotelkin, Alexander" uniqKey="Kotelkin A" first="Alexander" last="Kotelkin">Alexander Kotelkin</name></author><author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></author><author><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Communicable Diseases, Emerging (immunology)</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Flow Cytometry</term><term>Genetic Vectors (immunology)</term><term>Immunization (methods)</term><term>Newcastle disease virus (immunology)</term><term>SARS Virus (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Cytométrie en flux</term><term>Immunisation ()</term><term>Maladies transmissibles émergentes ()</term><term>Maladies transmissibles émergentes (immunologie)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vecteurs génétiques (immunologie)</term><term>Virus de la maladie de Newcastle (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Maladies transmissibles émergentes</term><term>Vaccins antiviraux</term><term>Vecteurs génétiques</term><term>Virus de la maladie de Newcastle</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Genetic Vectors</term><term>Newcastle disease virus</term><term>SARS Virus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Communicable Diseases, Emerging</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Flow Cytometry</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Cytométrie en flux</term><term>Immunisation</term><term>Maladies transmissibles émergentes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The international outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in 2002-2003 highlighted the need to develop pretested human vaccine vectors that can be used in a rapid response against newly emerging pathogens. We evaluated Newcastle disease virus (NDV), an avian paramyxovirus that is highly attenuated in primates, as a topical respiratory vaccine vector with SARS-CoV as a test pathogen. Complete recombinant NDV was engineered to express the SARS-CoV spike S glycoprotein, the viral neutralization and major protective antigen, from an added transcriptional unit. African green monkeys immunized through the respiratory tract with two doses of the vaccine developed a titer of SARS-CoV-neutralizing antibodies comparable with the robust secondary response observed in animals that have been immunized with a different experimental SARS-CoV vaccine and challenged with SARS-CoV. When animals immunized with NDV expressing S were challenged with a high dose of SARS-CoV, direct viral assay of lung tissues taken by necropsy at the peak of viral replication demonstrated a 236- or 1,102-fold (depending on the NDV vector construct) mean reduction in pulmonary SARS-CoV titer compared with control animals. NDV has the potential for further development as a pretested, highly attenuated, intranasal vector to be available for expedited vaccine development for humans, who generally lack preexisting immunity against NDV.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17535926</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>23</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.</ArticleTitle><Pagination><MedlinePgn>9788-93</MedlinePgn></Pagination><Abstract><AbstractText>The international outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in 2002-2003 highlighted the need to develop pretested human vaccine vectors that can be used in a rapid response against newly emerging pathogens. We evaluated Newcastle disease virus (NDV), an avian paramyxovirus that is highly attenuated in primates, as a topical respiratory vaccine vector with SARS-CoV as a test pathogen. Complete recombinant NDV was engineered to express the SARS-CoV spike S glycoprotein, the viral neutralization and major protective antigen, from an added transcriptional unit. African green monkeys immunized through the respiratory tract with two doses of the vaccine developed a titer of SARS-CoV-neutralizing antibodies comparable with the robust secondary response observed in animals that have been immunized with a different experimental SARS-CoV vaccine and challenged with SARS-CoV. When animals immunized with NDV expressing S were challenged with a high dose of SARS-CoV, direct viral assay of lung tissues taken by necropsy at the peak of viral replication demonstrated a 236- or 1,102-fold (depending on the NDV vector construct) mean reduction in pulmonary SARS-CoV titer compared with control animals. NDV has the potential for further development as a pretested, highly attenuated, intranasal vector to be available for expedited vaccine development for humans, who generally lack preexisting immunity against NDV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DiNapoli</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotelkin</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Elankumaran</LastName><ForeName>Subbiah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Samal</LastName><ForeName>Siba K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Bukreyev</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021821" MajorTopicYN="N">Communicable Diseases, Emerging</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009522" MajorTopicYN="N">Newcastle disease virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17535926</ArticleId><ArticleId IdType="pii">0703584104</ArticleId><ArticleId IdType="doi">10.1073/pnas.0703584104</ArticleId><ArticleId IdType="pmc">PMC1887550</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(1):150-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17050610</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Aug;11(8):1312-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16110580</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health Nations Health. 1952 Jun;42(6):672-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14924001</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Feb 13;24(7):1028-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16388880</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference><Reference><Citation>Microb Pathog. 2004 Jan;36(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">14643634</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1969 Apr;89(4):405-21</Citation><ArticleIdList><ArticleId IdType="pubmed">4305197</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Dec 5;330(1):8-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15527829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Sep;77(17):9522-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12915566</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Biol Stand. 1993;81:103-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8174792</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2004 Apr;42(4):1570-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15071006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2001 Dec;75(23):11868-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11689668</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Apr 30;304(5671):659-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15118129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Nov;80(21):10293-306</Citation><ArticleIdList><ArticleId IdType="pubmed">17041210</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1998 Feb;72(2):891-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9444980</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 May 23;103(21):8203-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16717196</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 May 2;23(24):3202-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15837221</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2000 Dec 5;278(1):168-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11112492</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jul;78(13):6938-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2005 Sep;112(1-2):24-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16022898</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Jan;77(2):1141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12502830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Gene Ther. 2006 May;17(5):500-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16716107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Feb;80(3):1130-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16414990</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Sci Tech. 2000 Aug;19(2):443-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10935273</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2000 Oct 15;19(4-5):483-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11027812</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Sep 30;340(2):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2006 Mar;87(Pt 3):641-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16476986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2005 Nov 21;202(10):1433-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16301748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Nov;79(21):13275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16227250</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hyg. 1963 Jul;78:29-60</Citation><ArticleIdList><ArticleId IdType="pubmed">14043545</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2001 Sep;82(Pt 9):2215-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11514732</ArticleId></ArticleIdList></Reference><Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Mol Ther. 2003 Dec;5(6):618-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14755888</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunol. 2004 Oct;16(10):1423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15314040</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name><name sortKey="Kotelkin, Alexander" sort="Kotelkin, Alexander" uniqKey="Kotelkin A" first="Alexander" last="Kotelkin">Alexander Kotelkin</name><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001985 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001985 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:17535926
|texte= Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17535926" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |